Oppenheimer Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $5
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Mazahir Alimohamed maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform and lowers the price target from $8 to $5.
Oppenheimer analyst Mazahir Alimohamed maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform and lowers the price target from $8 to $5.